STERTZER SIMON H purchased $104K of BCDA
STERTZER SIMON H purchased 109,200 shares of BioCardia, Inc. (BCDA) at an average of $0.95 ($0.92–$1.00, $0.10M total) across 2 trades over 2026-06-22 to 2026-06-23.
How this was made
The 30-second read
Why it matters
This is a primary-source insider buy, but it does not include new company performance, guidance, trial results, or regulatory actions that would typically drive repricing.
Market read
Traders may note the insider buy as a sentiment datapoint, but the filing alone is unlikely to change valuation without accompanying fundamental catalysts.
What to watch
No 10b5-1 plan is cited, but the article also provides no context on prior holdings, option exercises, or whether the director’s purchase was part of a broader pattern.
Background
The article is an SEC Form 4 insider transaction disclosure for BioCardia, Inc. (BCDA) by a director.
Ticker impact
BioCardia director Simon H Stertzer reported an open-market purchase of 109,200 shares at $0.9200 to $1.0000 between June 22-23.
Likely limited near-term impact; any effect is more sentiment than new business information.
Insider buys can be read as confidence, but this filing provides no new operational or financial metrics, and the transaction occurred days before the filing date.
Market effects
No clear sector read-through because the disclosure is a single-company insider transaction without new clinical or regulatory information.
None indicated.
None indicated.
Counterpoint
The buy may reflect routine liquidity needs, diversification, or non-informational timing rather than a change in outlook.
Key entities
- issuerBioCardia, Inc.
Company whose director reported an open-market purchase of shares via SEC Form 4.
- insiderSTERTZER SIMON H
Director who purchased 109,200 shares across two trades at $0.9200 to $1.0000.
